Cognitive functioning and lifetime Major Depressive Disorder in UK Biobank

De Nooij L[1][✉], Harris MA[1], Adams MJ[1], Clarke T-K[1], Shen X[1], Cox SR[2,3], McIntosh AM[1,2], Whalley HC[1]

[1]*Division of Psychiatry, University of Edinburgh, UK*

[2] *Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, UK*

[3]*Department of Psychology, University of Edinburgh, UK*

✉ Corresponding author. Email address: v1ldeno@ed.ac.uk

Abbreviated title: Cognition and lifetime depression

Word count: 3865 (main text only)

Abstract

Background. The degree of cognitive impairment associated with lifetime Major Depressive Disorder (MDD) remains uncertain. Previous UK Biobank studies have only shown limited evidence for population-level cognitive differences associated with probable MDD. Here, we used an updated range of cognitive tasks and clinical assessment criteria in UK Biobank to investigate whether there are differences in cognitive function associated with lifetime MDD.

Methods. Associations between lifetime MDD and cognition (performance on six tasks and a general (g) factor) were investigated in UK Biobank (N range 7,457-14,836, age 45-81 years, 52% female), adjusting for demographic, education and lifestyle. Classification of lifetime MDD was based on the Composite International Diagnostic Interview (CIDI-SF). Within the lifetime MDD group, we additionally explored relationships between cognition and (i) recurrent MDD, (ii) current MDD symptoms, (iii) severity of psychosocial impairment (while symptomatic), and (iv) concurrent psychotropic medication use

Results. Lifetime MDD was robustly associated with a lower g-factor (β = -0.10, q = 4.7·10^{-5}), with significant impairments in attention, processing speed and executive functioning ($\beta \geq$ 0.06). Analysis within the lifetime MDD group indicated that case individuals with severe psychosocial impairment had significantly lower g-factor (β = -0.14, P = 1.5·10^{-2}), with greatest impairments in reasoning (β = -0.18, q = 7.5·10^{-5}). Other clinical characteristics showed differential profiles of cognitive impairment across cognitive domains.

Conclusions. These findings reveal a modest negative association between lifetime MDD and cognitive performance. Specific cognitive domains showed greater deficits in relation to MDD characteristics, with greatest effects relating to psychosocial impairment.

KEYWORDS: cognition, depression, psychosocial functioning, medication, UK Biobank.

Introduction

Major Depressive Disorder (MDD) is a highly prevalent condition, affecting around one in five people in their lifetime globally (Bromet *et al.* 2011; Kessler & Bromet 2013; Otte *et al.* 2016). Not only has MDD been indicated as the leading cause of non-fatal disease burden (World Health Organization 2017), it is also estimated to contribute 10% to all-cause mortality as a consequence of suicide and increased risk to a range of medical illnesses (Cuijpers *et al.* 2014; Otte *et al.* 2016). Although MDD core symptoms centre around depressed mood and/or loss of interest, diagnostic criteria often include cognitive impairment, for instance in the form of "diminished ability to think or concentrate, or indecisiveness" (American Psychiatric Association 2013).

Previous clinical research has shown that individuals with MDD show cognitive deficits, particularly in executive functioning, working memory, attention, and processing speed (Lee *et al.* 2012; Snyder 2013; Rock *et al.* 2014; Wagner *et al.* 2015), as well as affect-related cognitive biases, including negative information biases for perception, attention, and memory (Roiser & Sahakian 2013; Lemoult & Gotlib 2019). Additionally, there is evidence that residual cognitive deficits are present in remitted cases (Hasselbalch *et al.* 2011; Bora *et al.* 2013; Rock *et al.* 2014). The degree and patterns of cognitive impairment in community-based individuals with lifetime MDD (with current or past symptoms) however remain uncertain, particularly since robust evidence from population-based studies is currently limited (Cullen *et al.* 2015, 2019). Furthermore, the patterns of cognitive impairment associated with clinical characteristics have not yet been fully explored.

It is well established that MDD usually is a highly recurrent condition, and that the experience of a past depressive episode increases the probability of a future depressive episode (Burcusa & Iacono 2007). It has therefore been proposed that disease-related psychological or biological changes may result in a predisposition to future depressive episodes, although these 'scar theories' are under continued debate (Burcusa & Iacono 2007). Alternatively, recurrent MDD could be viewed as more severe subtype. Either way, some studies suggest a cumulative negative effect of recurrent MDD episodes on cognition, but this effect has not been consistently reported and thus warrants further investigation (McClintock *et al.* 2010; Hasselbalch *et al.* 2011).

Although there is a general consensus that low mood can negatively affect cognitive performance, previous research has also been inconsistent as to whether impaired cognitive functioning is more pronounced in symptomatic individuals. For example, a population-based

study reported no association between depressive symptoms and cognitive functioning (Schweizer *et al.* 2018), and a meta-analysis showed largely comparable effect sizes for current and remitted MDD (Rock *et al.* 2014). In contrast, some studies show that symptomatic individuals may experience greater cognitive impairment (Hasselbalch *et al.* 2011; Lee *et al.* 2012), and another meta-analysis showed that cognitive functioning normalized after remission from MDD (Ahern & Semkovska 2017). There is thus a continued debate regarding the effect of clinical status (current versus remitted) on the association between MDD and cognitive impairment.

Of note, cognitive deficits in MDD have also been reported to be associated with impaired psychosocial functioning (Evans *et al.* 2014; Cambridge *et al.* 2018; Knight *et al.* 2018), which impacts on quality of life. Previous studies furthermore suggest that cognitive deficits are a mediator of decreased work performance, contributing to the overall cost attributable to MDD (Kessler *et al.* 2006; McIntyre *et al.* 2013). However, the relationship between psychosocial impairment while symptomatic and subsequent residual impairments in cognitive functioning (following recovery) has not been previously addressed, but may also be relevant to the disease burden of MDD.

Pharmacological treatment is also expected to have a complex influence on cognitive functioning, although reliable evidence is limited (Chakrabarty & Lam 2016). Meta-analyses suggest that some antidepressants may improve cognition (Keefe *et al.* 2014; Rosenblat *et al.* 2015). However, these results appear to be specific to particular treatments (McIntyre *et al.* 2017; Baune *et al.* 2018; Nierenberg *et al.* 2019), while for other treatments, medication side-effects may potentially affect cognitive performance negatively (Lee *et al.* 2012; Nagane *et al.* 2014; Cullen *et al.* 2015).

Taken together, previous studies suggest that individuals with MDD may experience modest impairments in previously implicated cognitive domains, i.e. executive functioning, working memory, attention and processing speed. Evidence, as described above, has been typically gleaned from clinical case-control studies which typically include small samples (N < 100) of specific patient groups (Chakrabarty & Lam 2016). They do however provide some evidence that the MDD characteristics recurrence, current symptoms, psychosocial impairment during the depressive episode, and concurrent use of psychotropic medication may affect the association between lifetime MDD and cognitive impairment. But to extend generalisability and understand the degree of impairment associated with lifetime MDD in the general population requires further investigation within a sufficiently powered community-based sample. Importantly, in order to detect modest cognitive effects, this will also require

the use of neuropsychological tests that target relevant cognitive domains, as well as sufficient performance variability within healthy populations.

Unlike clinical case-control studies, such large-scale population-based studies are not biased by specific sample characteristics and have the potential to detect likely modest effect sizes. They are however scarce on the topic of cognitive differences in adults with lifetime MDD, so that robust evidence from community-based samples regarding cognitive impairment in lifetime MDD is currently limited. Previous population-based studies have investigated baseline assessments of the UK Biobank cohort study (Cullen *et al.* 2015, 2019). Their findings indicated modestly decreased visuospatial memory performance in participants with lifetime MDD (Cullen *et al.* 2019), but showed comparable cognitive performance to controls for other cognitive measures. This indicates the need to further investigate population-level associations between lifetime MDD and cognitive impairment, taking into account clinical characteristics that may be relevant to this association.

UK Biobank is a large-scale adult population-based study, to which updated cognitive measures with improved reliability have been recently introduced (Lyall *et al.* 2016; Fawns-Ritchie & Deary 2019). These newer measures also cover a broader range of cognitive domains previously implicated in MDD (e.g. processing speed and executive functioning, as discussed above). Furthermore, previous mood disorder groupings relied on a combination of self-report and relatively unstructured questionnaire items, whereas the more recent lifetime MDD assessments were based on a structured diagnostic interview questionnaire, i.e. the Composite International Diagnostic Interview (CIDI-SF) (Kessler *et al.* 1998). These updated assessments provide an opportunity to further investigate patterns of cognition functioning in lifetime MDD within a large population-based sample.

In the current study we used this opportunity to examine whether lifetime MDD is associated to (residual) cognitive impairment, using UK Biobank follow-up cognitive assessments and new clinical definitions of MDD. Addressing limitations outlined above, we considered age and sex, level of education, and lifestyle factors (smoking, alcohol consumption and Body Mass Index [BMI]) as potential confounding variables (Lee *et al.* 2010; Gardener *et al.* 2015). We also examined characteristics of MDD cases that, as described above, are considered relevant to cognitive functioning in the context of lifetime MDD and may therefore influence the association: (i) recurrence of depressive episodes, (ii) current MDD symptomatology, (iii) severe psychosocial impairment (while symptomatic), and (iv) use of psychotropic medication (at time of assessment). These characteristics were

hypothesised to distinguish case subgroups with more severe cognitive impairment, or specifically for psychotropic medication, either increased or reduced impairment.

Methods

Participants

Adults (40 to 69 years) were recruited for participation in UK Biobank (http://www.ukbiobank.ac.uk) between 2006 and 2010 (Allen *et al.* 2012). The present study included participants with data for at least one of the neuropsychological test scores from the third UK Biobank assessment (2014 onwards; $N = 28,480$). Participants with self-reported neurological conditions were excluded from all analyses. A *g*-factor, representing general cognitive function, was derived from all remaining participants with complete data for included cognitive test measures ($N = 13,589$). When assessing individual tasks, complete cognitive data was not required. Participants with specific psychiatric disorders or an unclassified/missing lifetime MDD status were excluded from further analyses (Supplementary Materials 1 and Figure S1). Following exclusion criteria, $N = 14,877$ individuals ($n_{cases} = 4,486$, $M_{age} = 63.5$, $SD_{age} = 7.4$, age range 45-81 years, 52% female) were included across all analyses, with sample sizes ranging from $N = 7,457$ to $N = 14,386$ per case-control analysis.

Procedure

At the third assessment, participants visited the assessment centre where they provided demographic and health information in response to a series of touchscreen questions and completed computerised cognitive tests on a touchscreen. Medical history and current medication use were assessed during interviews led by health professionals. Furthermore, participants completed a web-based mental health questionnaire (MHQ) at home (Davis *et al.* 2019). Most participants (all those with complete cognitive data) completed the MHQ between 2.2 years before and 0.4 years after their assessment centre visit. UK Biobank received research ethics committee (REC) approval for the centre assessments (ref 11/NW/0382), later amended to also cover the MHQ, and all participants provided informed consent before assessment (http://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=200).

Major Depressive Disorder

Case-control classification

Case-control classification was based on the short form of the Composite International

Diagnostic Interview (CIDI-SF) (Kessler *et al.* 1998), administered as part of the MHQ (Davis *et al.* 2019). This included two binary questions regarding (i) ever having experienced depressive feelings or (ii) loss of interest, for a period of two or more weeks. Participants who responded 'Yes' to either question then answered a question about the lifetime number of depressive episodes, followed by six binary questions on experience of other DSM-IV MDD symptoms during their worst episode, including: (iii) feelings of worthlessness, (iv) tiredness, (v) difficulty concentrating, (vi) suicidal thoughts, (vii) changes in sleeping pattern, and (viii) changes in weight. Summed responses to all eight depression symptom questions provided a symptom score (range 0-8). Participants were also asked how often they had experienced depressive feelings / loss of interest during their worst episode, how long these feelings lasted, and whether they interfered with their "roles, life or activities" (psychosocial impairment). Participants were classified as lifetime MDD cases if all of the following applied (Davis *et al.* 2019):

i)   Summed symptom score >= five

ii)   At worst, symptoms experienced "almost every day" or "every day", and lasted "most of the day" or "all day"

iii)   Symptoms impaired psychosocial functioning "somewhat" or "a lot"

Clinical characteristics

Within individuals who were classified with lifetime MDD as described above, we further identified four clinical characteristics: (i) recurrent MDD, reflecting more than one depressive episode, (ii) putative current MDD symptoms, as derived from responses on the touchscreen questionnaire (Supplementary Materials 2), (iii) severe psychosocial impairment (at the time of the depressive episode), indicated by the maximum CIDI-SF symptom score of eight in combination with the maximum score for psychosocial impairment (Davis *et al.* 2019); and (iv) concurrent use of psychotropic medication, which was derived from reported use of antidepressant (94.6%), antipsychotic (3.9%) or anxiolytic (1.5%) medication as assessed during the nurse-led interview (Figure S2 in Supplementary Materials 3).

Cognition

In the current study we considered cognitive tests from the third UK Biobank assessment. We included data from the following cognitive tests:

i)   Digit Symbol Substitution test (DSST)

ii)   Trail Making Test, alphanumeric trail (TMT-B)

iii)   Numeric Memory (NM)

iv)   Matrix pattern completion (Matrix)

v)   Verbal Numeric Reasoning (VNR)

vi)   Tower rearranging (Tower)

This selection comprises all updated cognitive test data available at time of analysis (DSST, TMT-B, Matrix, Tower), and additionally included two cognitive tests repeated at this assessment that were also administered at earlier UK Biobank assessments (VNR, NM). Further details on each cognitive test can be found in Table 1. Psychometric properties, advantages and limitations of the UK Biobank cognitive tests have been discussed in detail elsewhere (Fawns-Ritchie & Deary 2019).

[Table 1 Here]

Education and Lifestyle

Measures of education, alcohol consumption and smoking were derived from touchscreen questionnaire responses (Supplementary Materials 4). For education, a multiple-choice question allowed participants to report all qualifications. Participants were classified into one of five categories depending on the highest qualification they had attained. Alcohol consumption was measured as alcohol units per week (Clarke *et al.* 2017). Past smokers were categorised by pack years (Field name: 20161; Wain *et al.* 2015) quartiles, with participants who had never regularly smoked in a fifth category. BMI (in kg/m^2) was derived by the UK Biobank team from physical measurements (Field name: 21001).

Statistical Analysis

Statistical analyses were performed in R (version 3.2.3). Continuous variables were visually inspected and log-transformed where necessary to more closely approximate normal distribution. We reversed the TMT-B variable before statistical modelling, so that for all tests, higher scores represented better performance. For all outcome variables, negative regression coefficients thus indicated negative associations with cognitive performance. Regression coefficients are standardised throughout. Significance level was determined by a two-tail threshold of $\alpha = .05$.

Derivation of g-factor

We derived a *g*-factor as single measure of general cognitive functioning (Johnson *et*

al. 2008) by application of Principal Component Analysis (R function 'prcomp') including only complete observations (n = 13,589), extracting scores on the first principal component. This derived *g*-factor accounted for 45.0% of the test score variance. Component loadings of the model were all in the expected direction (loadings range 0.34 to 0.47; Table S1 and Figure S3).

Statistical Modelling

Associations between lifetime MDD and cognitive performance were tested using linear models. Each model included lifetime MDD as the predictor of interest and a cognitive score as the outcome variable. Primary models included age and sex as confounds (Tables 2 and 3). Additional models also included (i) education, (ii) lifestyle factors (alcohol, smoking and BMI), and (iii) both education and lifestyle factors (full model) as potential confounds. All results were false discovery rate (FDR) corrected across the 24 test-specific models and separately across the four *g*-factor models.

With the aim of exploring whether cognitive performance related to specific clinical features of depression, we also examined relationships, within the case group only, with recurrent depression, putative current depressive symptoms, impact on psychosocial functioning, and psychotropic medication use. Firstly, we tested a linear model including participants classified with lifetime MDD only (n = 2,179; Figure 2A) that predicted *g*-factor from all four clinical characteristics, including age and sex as covariates. Given the large degree of overlap between clinical characteristics within our sample, these variables were entered as simultaneous predictors in order to model their unique contributions to cognitive functioning. Secondly, we further explored whether the four clinical characteristics were associated with differential profiles of cognitive performance. Using the same approach, we tested another six univariate linear models (applying FDR-correction) that predicted each cognitive test scores from all four clinical characteristics, including age and sex as covariates.

Results

Sample Characteristics

Table 2 summarises demographic and lifestyle information on participants who completed all cognitive tests. The MDD group included a higher proportion of females (45.6% of controls, 67.2% of cases, $\chi^2_{(1)}$ = 293.2, $P < 2.2 \cdot 10^{-16}$). MDD cases were also younger (*M* difference = 2.2 years, $t_{(4357.9)}$ = 12.1, $P < 2.2 \cdot 10^{-16}$), had higher BMI (*Mdn* difference = 0.7 kg/m^2, $H_{(1)}$ = 40.1, $P = 2.4 \cdot 10^{-10}$), were more often lifetime regular smokers

(20.7% of controls, 27.9% of cases, $\chi^2_{(1)} = 46.0$, $P = 1.2 \cdot 10^{-11}$), and among smokers, they had smoked more cigarettes (*Mdn* difference = 1.8 pack years, $H_{(1)} = 7.8$, $P = 5.3 \cdot 10^{-3}$). Conversely, control group participants reported more alcohol consumption (*Mdn* difference = 1.7 units/week, $H_{(1)} = 46.6$, $P = 8.7 \cdot 10^{-12}$). Education did not significantly differ between groups ($\chi^2_{(4)} = 5.6$, $P = .23$). Case and control sample sizes for individual cognitive tests, as well as test descriptive statistics, can be found in Table S2 (Supplementary Materials 6).

[Table 2 Here]

Associations between lifetime MDD and cognitive performance

Results indicated significant associations between lifetime MDD and cognitive performance (Table 3). The primary models consistently showed lower cognitive performance for the case group relative to controls with small effect sizes in terms of the *g*-factor ($\beta = -0.10$, $q = 4.7 \cdot 10^{-5}$) and four of the six cognitive tests (DSST, $\beta = -0.13$, $q = 1.1 \cdot 10^{-7}$; TMT-B, $\beta = -0.08$, $q = 1.1 \cdot 10^{-3}$; VNR, $\beta = -0.06$, $q = 2.0 \cdot 10^{-3}$; Tower, $\beta = -0.06$, $q = 3.4 \cdot 10^{-2}$) (Figure 1). These results were robust over subsequent models that additionally included confounding variables, and almost all significant results (except for the Tower lifestyle model) survived multiple comparison correction. Associations between cognitive performance and confounding variables are reported in Supplementary Materials 7.

[Table 3 Here]

[Figure 1 Here]

Associations between clinical characteristics and cognitive performance

For the associations between clinical characteristics and cognitive impairment, as measured by *g*-factor, we found no effect of recurrent depression ($\beta = 0.02$, $P = .56$), and a very modest, non-significant point estimate for putative current symptoms at time of assessment ($\beta = -0.07$, $P = .15$). Conversely, severe psychosocial impairment during the depressive episode was significantly associated with lower *g*-factor ($\beta = -0.14$, $P = 1.5 \cdot 10^{-2}$). Use of psychotropic medication showed a small, non-significant point estimate for its association with general cognitive functioning ($\beta = -0.10$, $P = .10$).

Further exploration within the lifetime MDD case group revealed differential cognitive profiles related to clinical characteristics (Figure 2B-E, Table S4 in Supplementary Materials 8). Severe psychosocial impairment was associated with worse VNR performance ($\beta = -0.18$, $P = 1.2 \cdot 10^{-5}$, $q = 7.5 \cdot 10^{-5}$). Furthermore, results indicated nominally significant associations

with lower TMT-B performance for severe psychosocial impairment (β = -0.11, P = 2.3·10^{-2}, q = 0.07) and psychotropic medication (β = -0.13, P = 2.7·10^{-2}, q = 0.16).

[Figure 2 Here]

Discussion

The findings of the current study describe a robust association between lifetime MDD and lower general cognitive performance within a population-based sample. The DSST, TMT-B, VNR and Tower results further indicate that executive functioning, processing speed and aspects of reasoning were predominantly affected. These effects were of modest overall effect size (β = -0.10 for general cognitive performance), suggesting that they are of limited clinical relevance, although such differences may have substantial consequences for whole populations. Comparisons within the case group however showed that severe impact on psychosocial functioning (while symptomatic) and use of psychotropic medication (at time of assessment) predicted the lowest measures of cognitive performance. These clinical characteristics also showed differential profiles of cognitive impairment, whereby severe psychosocial impairment was associated with reasoning (VNR) deficits. Severe psychosocial impairment, along with use of psychotropic medication, were also related to moderately lower mental flexibility and processing speed (TMT-B). These results highlight that cognitive functioning is impaired among individuals with current but also past MDD, and that deficits within specific cognitive domains may be more pronounced – and therefore of potential clinical relevance – in relation to impact of the depressive episode on psychosocial functioning (after recovery) and continued use of psychotropic medication.

The present investigation robustly indicated lower (general) cognitive functioning in lifetime MDD within a healthy adult population-based sample, although with small effect sizes. Meta-analyses of small case-control studies have previously indicated cognitive deficits in lifetime MDD within the domains of executive functioning, memory and attention (e.g. Rock *et al.* 2014). This study corroborates previous findings that suggest cognitive deficits are apparent after remission from MDD, but we also note that these population-level effect sizes are smaller than in traditional case-control studies. Of note, psychosocial impairment while symptomatic was also significantly associated with greater cognitive deficits in individuals with lifetime MDD, and we found some evidence for an association between psychotropic medication use and lower processing speed. This implicates that clinical studies that recruit

from treatment centres, and thereby include participants from a patient group more likely to experience severe psychosocial impairment and/or use psychotropic medication, may show inflated effect sizes in comparison with the general population because of their sample characteristics.

Psychosocial impairment during the depressive episode was found to be associated to lower cognitive functioning at time of subsequent assessment, suggesting that the impact of a depressive episode on quality of life may not be limited to the symptomatic phase. This result is consistent with previous adult clinical studies (Cambridge *et al.* 2018) and may reflect a subgroup of remitted individuals vulnerable to cognitive impairment, who potentially also experienced greater cognitive deficits during the depressive episode. Previous clinical research showed that cognitive impairment in remitted MDD was associated with psychosocial dysfunction in the subdomains if occupational functioning, leisure time and subjective cognition (Knight *et al.* 2018). Future research will need to address whether cognitive impairment in remitted MDD also relates to persistent functional impairment in daily life within specific subgroups of individuals, or more general on a population-level.

Findings of the current study did not indicate robust associations between cognitive impairment and recurrent depressive episodes, current MDD symptoms, or use of psychotropic medication. Thus, within the healthy and non-clinical UK Biobank population, these MDD characteristics were of limited relevance to the association between lifetime MDD and cognitive impairment. Instead our findings suggest that psychosocial impairment during the depressive episode may impact on cognitive functioning even after recovery.

The current study adds to previous UK Biobank research, showing some important differences. Firstly, the current study examined neuropsychological test measures which were not previously investigated within the UK Biobank sample to address cognitive differences related to MDD. These tests were also expected to be sensitive to cognitive impairments hypothesised for individuals with lifetime MDD (e.g. DSST, Jaeger 2018). Furthermore, the current study implemented CIDI-based criteria for lifetime MDD classification, which may be of more specific clinical relevance due to close correspondence with DSM criteria than previous definitions.

Although the study benefited from the availability of newer, more reliable cognitive assessments in UK Biobank, this did impose the limitation of a cross-sectional design. We also note that the classification of lifetime MDD was based on the CIDI-SF, which, although based on diagnostic criteria and well validated, is still limited by reliance on retrospective self-report. Furthermore, given the aim of the current study to investigate (residual) cognitive

impairment associated with lifetime MDD in the general adult population, the mid-late life age range of UK Biobank participants at the time of the third assessment could also be considered a limitation. However, the cohort has been previously described as a relatively healthy mid-late life cohort (Davis *et al.* 2019), and potential confounding effects of age-related cognitive decline were further mitigated by excluding individuals with reported neurological or degenerative conditions from the current study. Large-scale longitudinal research will be needed to unravel the relationship between MDD and cognitive impairment over the disease course as well as the lifespan.

In summary, the present findings suggest that lifetime MDD relates to impaired cognitive functioning among older adults with most prominent deficits in the cognitive domain of processing speed (DSST). Severe psychosocial impairment was associated with greater overall cognitive impairment, and specifically on tasks of reasoning (VNR) and mental flexibility and processing speed (TMT-B). Furthermore, clinical characteristics showed differential profiles of impairment of modest effect. These findings provide an important foundation for future studies addressing cognitive functioning in the context of MDD. Longitudinal trajectories of cognitive performance in lifetime MDD and the differential influences of pharmacological treatments on these trajectories are important targets for further research. The longitudinal association between report of psychosocial impairment while symptomatic and subsequent cognitive impairment, also when remitted, reflects their likely impact on quality of life and suggest that both cognitive and psychosocial functioning should be key targets in the treatment of MDD.

Supporting information

Supplementary Materials can be found in the online version of this article. The R code of our statistical analysis will be made available via [link] after publication.

Acknowledgements

We would like to thank all of the participants from UK Biobank who have shown their continued commitment, as well as the UK Biobank team for collecting and providing the data.

Financial support

This work was supported by Wellcome Trust (A.M.M., grant number 104036/Z/14/Z) and the Medical Research Council (A.M.M., grant number MC_PC_17209), (S.R.C., grant numbers MR/M013111/1, MR/R024065/1).

Conflicts of interest

The authors have declared no competing or potential conflicts.

Ethical standards

The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

Correspondance to

Laura de Nooij, Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh EH10 5HF, UK. Email: v1ldeno@ed.ac.uk

References

Ahern E, Semkovska M (2017). Cognitive functioning in the first-episode of Major Depressive Disorder: A systematic review and meta-analysis. *Neuropsychology* **31**, 52–72.

Allen N, Sudlow C, Downey P, Peakman T, Danesh J, Elliott P, Gallacher J, Green J, Matthews P, Pell J, Sprosen T, Collins R (2012). UK Biobank: Current status and what it means for epidemiology. *Health Policy and Technology* **1**, 123–126.

American Psychiatric Association (2013). *Diagnostic and Statisctical Manual of Mental Disorders, 5th Edition: DSM-5*. American Psychiatric Publishing, Inc.: Arlington, VA, US.

Baune BT, Brignone M, Larsen KG (2018). A network meta-Analysis comparing effects of various antidepressant classes on the digit symbol substitution test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder. *International Journal of Neuropsychopharmacology* **21**, 97–107.

Bora E, Harrison BJ, Yu M (2013). Cognitive impairment in euthymic major depressive disorder: a meta-analysis. *Psychological Medicine* **43**, 2017–2026.

Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, de Graaf R, Demyttenaere K, Hu C, Iwata N, Karam AN, Kaur J, Kostyuchenko S, Lépine J-P, Levinson D, Matschinger H, Mora MEM, Brown MO, Posada-Villa J, Viana MC, Williams DR, Kessler RC (2011). Cross-national epidemiology of DSM-IV major depressive episode. *BMC Medicine* **9**

Burcusa SL, Iacono WG (2007). Risk for recurrence in depression. *Clinical Psychology Review* **27**, 959–985.

Cambridge OR, Knight MJ, Mills N, Baune BT (2018). The clinical relationship between cognitive impairment and psychosocial functioning in major depressive disorder: A systematic review. *Psychiatry Research* **269**, 157–171.

Chakrabarty T, Lam RW (2016). Cognitive dysfunction in Major Depressive Disorder: Assessment, impact and management. *Neuropsychology* **31**, 52–72.

Clarke T-K, Adams MJ, Davies G, Howard DM, Hall LS, Padmanabhan S, Murray AD, Smith BH, Campbell A, Hayward C, Porteous DJ, Deary IJ, McIntosh AM (2017). Genome-wide association study of alcohol consumption and genetic overlap with other health-related traits in UK Biobank (N = 112 117). *Molecular Psychiatry* **22**, 1376–1384.

Cuijpers P, Vogelzangs N, Twisk J, Kleiboer A, Li J, Penninx BW (2014). Comprehensive Meta-Analysis of Excess Mortality in Depression in the General Community Versus Patients With Specific Illnesses. *American Journal of Psychiatry* **171**, 453–462.

Cullen B, Nicholl BI, Mackay DF, Martin D, Ul-haq Z, McIntosh A, Gallacher J, Deary IJ, Pell JP, Evans JJ, Smith DJ (2015). Cognitive function and lifetime features of depression and bipolar disorder in a large population sample: Cross-sectional study of 143,828 UK Biobank participants. *European Psychiatry* **30**, 950–958.

Cullen B, Smith DJ, Deary IJ, Pell JP, Keyes KM, Evans JJ (2019). Understanding cognitive impairment in mood disorders: Mediation analyses in the UK Biobank cohort. *British Journal of Psychiatry*, 1–8.

Davis KAS, Coleman JR, Adams M, Allen N, Breen G, Cullen B, Dickens C, Fox E, Graham N, Holliday J, Howard LM, John A, Lee W, McCabe R, McIntosh A, Pearsall R, Smith DJ, Sudlow C, Ward J, Zammit S, Hotopf M (preprint published on 5 August 2019). Mental Health in UK Biobank Revised – development, implementation and results from an online questionnaire completed by 157,366 participants. *medRxiv*, 1–20. https://doi.org/10.1101/19001214

Evans VC, Iverson GL, Yatham LN, Lam RW (2014). The relationship between neurocognitive and psychosocial functioning in Major Depressive Disorder: A systematic review. *Journal of Clinical Psychiatry* **75**, 1359–1370.

Fawns-Ritchie C, Deary IJ (preprint published on 15 July 2019). Reliability and validity of the UK Biobank cognitive tests. *medRxiv*, 1–26. https://doi.org/10.1101/19002204

Gardener H, Wright CB, Rundek T, Sacco RL (2015). Brain health and shared risk factors for dementia and stroke. *Nature Reviews Neurology* **11**, 651–657.

Hasselbalch BJ, Knorr U, Kessing LV (2011). Cognitive impairment in the remitted state of unipolar depressive disorder: A systematic review. *Journal of Affective Disorders* **134**, 20–31.

Jaeger J (2018). Digit Symbol Substitution Test The Case for Sensitivity Over Specificity in Neuropsychological Testing. *Journal of Clinical Psychopharmacology* **38**, 513–519.

Johnson W, te Nijenhuis J, Bouchard TJ (2008). Still just 1 g: Consistent results from five test batteries. *Intelligence* **36**, 81–95.

Keefe RSE, McClintock SM, Roth RM, Doraiswamy PM, Tiger S, Madhoo M (2014).

Cognitive effects of pharmacotherapy for Major Depressive Disorder: A systematic review. *Journal of Affective Disorders* **75**, 864–876.

Kessler RC, Akiskal HS, Ames M, Birnbaum H, Greenberg P, Hirschfeld RMA, Jin R, Merikangas KR, Wang PS (2006). The prevalence and effects of mood disorders on work performance in a nationally representative sample of US workers. *American Journal of Psychiatry* **163**, 1561–1568.

Kessler RC, Andrews G, Mroczek D, Ustün TB, Wittchen HU (1998). The World Health Organization Composite International Diagnostic Interview Short-Form (CIDI-SF). *International Journal of Methods in Psychiatric Research* **7**, 171–185.

Kessler RC, Bromet EJ (2013). The epidemiology of depression across cultures. *Annual Review of Public Health* **24**, 119–138.

Knight MJ, Air T, Baune BT (2018). The role of cognitive impairment in psychosocial functioning in remitted depression. *Journal of Affective Disorders* **235**, 129–134.

Lee RSC, Hermens DF, Porter MA, Redoblado-hodge MA (2012). A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder. *Journal of Affective Disorders* **140**, 113–124.

Lee Y, Back JH, Kim J, Kim S, Na DL, Cheong H-K, Hong CH, Kim YG (2010). Systematic review of health behavioral risks and cognitive health in older adults. *International Psychogeriatrics* **22**, 174–187.

Lemoult J, Gotlib IH (2019). Depression: A cognitive perspective. *Clinical Psychology Review* **69**, 51–66.

Lyall DM, Cullen B, Allerhand M, Smith DJ, Mackay D, Evans J, Anderson J, Fawns-Ritchie C, McIntosh AM, Deary IJ, Pell JP (2016). Cognitive Test Scores in UK Biobank: Data Reduction in 480,416 Participants and Longitudinal Stability in 20,346 Participants. *PLoS One* **11**, 1–10.

McClintock SM, Husain MM, Greer TL, Cullum CM (2010). Association between depression severity and neurocognitive function in Major Depressive Disorder: A review and synthesis. *American Psychological Association* **24**, 9–34.

McIntyre RS, Cha DS, Soczynska JK, Woldeyohannes HO, Gallaugher LA, Kudlow P, Alsuwaidan M, Baskaran A (2013). Cognitive deficits and functional outcomes in Major

Depressive Disorder: Determinants, substrates and treatment interventions. *Depression and Anxiety* **30**, 515–527.

McIntyre RS, FLorea I, Tonnoir B, Loft H, Lam RW, Cronquist Christensen M (2017). Efficacy of Vortioxetine on cognitive functioning in patient with Major Depressive Disorder. *Journal of Clinical Psychiatry* **78**, 115–121.

Nagane A, Baba H, Nakano Y, Maeshima H, Hukatsu M, Ozawa K, Suzuki T, Arai H (2014). Comparative study of cognitive impairment between medicated and medication-free patients with remitted major depression: Class-specific influence by tricyclic antidepressants and newer antidepressants. *Psychiatry Research* **218**, 101–105.

Nierenberg AA, Loft H, Olsen CK (2019). Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine. *Journal of Affective Disorders* **250**, 35–42.

Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, Mohr DC, Schatzberg AF (2016). Major depressive disorder. *Nature Reviews Disease Primers* **2**, 16065.

Rock PL, Roiser JP, Riedel WJ, Blackwell AD (2014). Cognitive impairment in depression: a systematic review and meta-analysis. *Psychological Medicine* **44**, 2029–2040.

Roiser JP, Sahakian BJ (2013). Hot and cold cognition in depression. *CNS Spectrums* **18**, 139–149.

Rosenblat JD, Kakar R, McIntyre RS (2015). The cognitive effects of antidepressants in Major Depressive Disorder: A systematic review and meta-analysis of Randomized Clinical Trials. *International Journal of Neuropsychopharmacology*, 1–13.

Schweizer S, Kievit RA, Emery T, Cam-CAN, Henson RN (2018). Symptoms of depression in a large healthy population cohort are related to subjective memory complaints and memory performance in negative contexts. *Psychological Medicine* **48**, 104–114.

Snyder HR (2013). Major Depressive Disorder is associated with broad impairments on neuropsychological measures of executive function: A meta-analysis and review. *Psychological Bulletin* **139**, 81–132.

Wagner S, Müller C, Helmreich I, Huss M, Tadić A (2015). A meta-analysis of cognitive functions in children and adolescents with major depressive disorder. *European Child &*

Adolescent Psychiatry **24**, 5–19.

Wain L V, Shrine N, Miller S, Jackson VE, Ntalla I, Artigas MS, Billington CK, Kheirallah AK, Allen R, Cook JP, Probert K, Obeidat M, Bossé Y, Hao K, Postma DS, Paré PD, Ramasamy A, UKBEC, Mägi R, Mihailov E, Rainmaa E, Melén E, O'Conell J, Frangou E, Delaneau O, OxGSK-Consortium, Freeman C, Petkova D, McCarthy M, Sayers I, Daloukas P, Hubbard R, Pavord I, Hansell AL, Thomson NC, Zeggini E, Morris AP, Marchini J, Strachan DP, Tobin MD, Hall IP (2015). Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank. *Lancet Respiratory Medicine* **3**, 769–781.

World Health Organization (2017). *Depression and Other Common Mental Disorders: Global Health Estimates.* Geneva: World Health Organization, 2017

Tables and Figures

Table 1. Descriptions of cognitive tests

Test	Description	Cognitive domains	Variable	Range
DSST	Presented with a key grid containing digit-symbol pairs, the participant had one minute to indicate which number corresponded to each of the symbols in the task grid.	Processing speed and attention	Total correct score	0-89
TMT-B	Digits and letters were scattered around the screen in circles. The participant was asked to click on them sequentially, alternating between digits and letters (1-A-2-B-3-C etc.)	Executive functions (mental flexibility, complex attention) and processing speed	Time to completion (s) *reversed in analyses*	20-300
NM	Every trial, a sequence of digits was briefly presented on screen, after which the participant was asked to recollect it from memory. If answered correctly, the sequence length increased with one digit.	Working memory and attention	Maximum digits remembered correctly	2-12
Matrix	Presented with a series of matrix pattern blocks that each missed one element, the participant was asked to select the element that best completed the pattern from a range of choices.	Reasoning ability (abstract)	Total correct score	0-15
VNR	The participant had two minutes to complete as many multiple choice reasoning questions as possible.	Reasoning ability (verbal, numeric) and processing speed	Total correct score	0-13
Tower	Presented with a series of illustrations displaying three differently-coloured hoops on three pegs, the participant was asked how many moves it would take to re-arrange the hoops into another specific position.	Executive functions (strategy, planning) and working memory	Total correct score	0-18

DSST, Digit Symbol Substitution Task; Matrix, Matrix pattern completion; NM, Numeric Memory; TMT-B, Trail Making Test B (alphanumeric trail); Tower, Tower rearranging; VNR, Verbal Numeric Reasoning.

Table 2. Demographic variables for participants who completed all cognitive tasks.

	Control *n = 5,221*	*Case* *n = 2,236*	*Effect Size*
Age (years), mean (SD)[a]	64.7 (7.3)	62.5 (7.1)	0.30[A]***
Sex female, *n* (%)[b]	2,379 (45.6)	1,503 (67.2)	0.20[B]***
Education[b]			n.s.
Incomplete, *n* (%)	263 (5.0)	87 (3.9)	
Compulsory, *n* (%)	600 (11.5)	267 (11.9)	
Continued, *n* (%)	304 (5.8)	121 (5.4)	
College, *n* (%)	1,327 (25.4)	561 (25.1)	
University, *n* (%)	2,710 (51.9)	1,188 (53.1)	
Missing data, *n* (%)	17 (0.3)	12 (0.5)	
Alcohol units[c]			0.007[C]***
Median (IQR)	10.7 (15.6)	9.0 (14.9)	
Missing data, *n* (%)	317 (6.1)	162 (7.2)	
Smoking			
Lifetime regular smoker, *n* (%)[b]	1,079 (20.7)	624 (27.9)	0.08[B]***
Pack years, median (IQR)[c]	14.8 (17.5)	16.5 (22.4)	0.005[C]**
Missing data, *n* (%)	86 (1.6)	34 (1.5)	
BMI[c]			0.006[C]***
Median (IQR)	25.5 (5.0)	26.2 (6.0)	
Missing data, *n* (%)	204 (4.6)	112 (5.0)	

n.s. = non-significant , *$P < .05$, **$P < .01$, ***$P < .001$

[a] Independent t-test, [A] Hedge's *g*

[b] Chi-squared test, [B] Cramer's *V*

[c] Kruskal Wallis test, [C] η^2

BMI, Body Mass Index; IQR, Interquartile Range; SD, Standard Deviation.

Table 3. Linear model coefficients for the association between lifetime mood disorder and cognitive performance.

	Model 1 *Primary model*	Model 2 *(+ Education)*	Model 3 *(+ Lifestyle)*	Model 4 *Full model*
g-factor				
β-coefficient	**-0.10*****	**-0.10*****	**-0.08*****	**-0.10*****
(95% CI)	(-0.15,-0.05)	(-0.15,-0.06)	(-0.14,-0.03)	(-0.15,-0.05)
DSST				
β-coefficient	**-0.13*****	**-0.13*****	**-0.12*****	**-0.13*****
(95% CI)	(-0.18,-0.09)	(-0.18,-0.09)	(-0.17,-0.08)	(-0.18,-0.08)
TMT-B				
β-coefficient	**-0.08*****	**-0.08*****	**-0.08****	**-0.09*****
(95% CI)	(-0.13,-0.04)	(-0.13,-0.04)	(-0.13,-0.03)	(-0.14,-0.04)
NM				
β-coefficient	-0.03	-0.03	-0.02	-0.03
(95% CI)	(-0.08,0.02)	(-0.08,0.01)	(-0.07,0.03)	(-0.08,0.02)
Matrix				
β-coefficient	-0.03	-0.03	0.00	-0.01
(95% CI)	(-0.07,0.02)	(-0.08,0.02)	(-0.05,0.06)	(-0.06,0.04)
VNR				
β-coefficient	**-0.06*****	**-0.06*****	**-0.05***	**-0.07*****
(95% CI)	(-0.10,-0.03)	(-0.10,-0.03)	(-0.09,-0.01)	(-0.10,-0.03)
Tower				
β-coefficient	**-0.06***	**-0.06***	-0.05*	**-0.06***
(95% CI)	(-0.11,-0.01)	(-0.11,-0.01)	(-0.11,0.00)	(-0.11,-0.01)

* $P < .05$, ** $P < .01$, *** $P < .001$, **bold** $q < .05$ CI, Confidence Interval; DSST, Digit Symbol Substitution Task; *g*-factor, derived measure of general cognitive performance; Matrix, Matrix pattern completion; NM, Numeric Memory; TMT-B, Trail Making Test, alphanumeric trail; Tower, Tower rearranging; VNR, Verbal Numeric Reasoning.

*P < .05, ** P < .01, *** P < .001

DSST, Digit Symbol Substitution Task; *g*-factor, derived measure of general cognitive performance; Matrix, Matrix pattern completion; NM, Numeric Memory; TMT-B, Trail Making Test, alphanumeric trail; Tower, Tower rearranging; VNR, Verbal Numeric Reasoning.

Figure 1. Visualisation of the base model results for (A) *g*-factor, (B) DSST, (C) TMT-B, (D) NM, (E) Matrix, (F) VNR, and (G) Tower. Graphs display case-control group differences in cognitive performance after adjustment for confounders (i.e. age and sex were regressed out). Specifically, they show significant but modest associations of lifetime MDD classification with lower general cognitive performance (*g*-factor), and with lower performance on DSST, TMT-B, VNR, and Tower.

A) Participants classified with lifetime MDD

With clinical characteristics, *n* = 1,574

Putative current symptoms (*n* = 469)

Severe psychosocial impairment (*n* = 338)

Recurrent (*n* = 1,358)

Psychotropic medication (*n* = 308)

Without clinical characteristics, *n* = 605

Excluded due to unknown number of depressive episodes, *n* = 57

B) Recurrent

C) Putative current symptoms

D) Severe psychosocial impairment

E) Psychotropic medication

*P < .05, ** P < .01, *** P < .001*

Figure 2. (A) Venn diagram of all participants classified with lifetime MDD and each of the four the clinical characteristics recurrent depression, putative current symptoms, severe psychosocial impairment, and psychotropic medication. These clinical characteristics were investigated within the group of case participants. (B-E) Cognitive profiles associated with the clinical characteristics (B) recurrent depression, (C) putative current symptoms, (D) severe psychosocial impairment (while symptomatic), and (E) use of psychotropic medication (at time of assessment). Points represent points estimates of the β-coefficient within the case models, whereas lines reflect the 95% confidence interval of the β-coefficient.